The patient is at the core of BioAlliance Pharma’s concerns.
We have chosen to devote our efforts to severe diseases – cancer, opportunistic infections – to provide the most appropriate response to complex, resistant disorders. Our drugs enable more effective targeted therapies to be applied, but also seek to improve patients’ quality of life. New administration routes limiting the number of doses to be administered are developed by our teams to simplify the life of patients. We mobilize our resources to serve our patients in order to be a genuine health industry player and respond to unmet medical needs.
We have created research alliances with the main academic centers of excellence in our areas of specialization: CNRS, Inserm, IGR, Pasteur, ENS, Universities and hospitals. We use cutting edge research to develop new therapeutic applications. The innovations resulting from these collaborations are developed in-house through ongoing teamwork covering all competencies, from research to market.
Our business also involves integrating quality at all levels, particularly in the areas of research, development, pharmaceutical production, and marketing. Our “quality assurance” department is involved in all the company’s activities in order to promote “best practices” and “good corporate governance” rules.
Our role is to offer novel healthcare solutions. For us, this important mission goes hand in hand with high-level ethics that we apply daily, both internally and with all our partners, but also with respect for the environment and for others, based on a concern for sustainable growth.